Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Introduction Multiple myeloma (MM) is a malignancy derived from terminally differentiated plasma cells and has become the second most prevalent hematological cancer (1). Extramedullary disease (EMD) ...

Both BMY’s Pomalyst and Revlimid are approved for multiple myeloma. Sanofi is also evaluating a fixed-dose subcutaneous (“SC”) formulation of Sarclisa for the treatment of R/R MM.

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...